Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 9:3:100037.
doi: 10.1016/j.crneur.2022.100037. eCollection 2022.

Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation

Affiliations
Review

Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation

Najam A Sharif. Curr Res Neurobiol. .

Abstract

Eyesight is the most important of our sensory systems for optimal daily activities and overall survival. Patients who experience visual impairment due to elevated intraocular pressure (IOP) are often those afflicted with primary open-angle glaucoma (POAG) which slowly robs them of their vision unless treatment is administered soon after diagnosis. The hallmark features of POAG and other forms of glaucoma are damaged optic nerve, retinal ganglion cell (RGC) loss and atrophied RGC axons connecting to various brain regions associated with receipt of visual input from the eyes and eventual decoding and perception of images in the visual cortex. Even though increased IOP is the major risk factor for POAG, the disease is caused by many injurious chemicals and events that progress slowly within all components of the eye-brain visual axis. Lowering of IOP mitigates the damage to some extent with existing drugs, surgical and device implantation therapeutic interventions. However, since multifactorial degenerative processes occur during aging and with glaucomatous optic neuropathy, different forms of neuroprotective, nutraceutical and electroceutical regenerative and revitalizing agents and processes are being considered to combat these eye-brain disorders. These aspects form the basis of this short review article.

Keywords: Axonal injury; Glaucoma; Intraocular pressure; Neurodegeneration; Neuroprotection; Optic nerve; Retina; Retinal ganglion cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Anatomical location and connections between the eyes and the brain structures involved in visual information capture, transmission and perception upon decoding.
Fig. 2
Fig. 2
Cartoon of the anterior segment of the human eye depicting key structures producing and draining the AQH is shown.
Fig. 3
Fig. 3
Schematic illustration of the many sites of damage that can occur within the eye-brain axis due to chronically elevated IOP in POAG.
Fig. 4
Fig. 4
Cartoon showing how raised IOP bulges the eye and causes mechanical pressure to radiate to all part of the eye but in particular how and where it causes damages at the ONH/LC regions (A). The molecular and cellular components affected by the elevated IOP at the level of the ONH/LC and optic nerve are depicted in more detail in panel B.
Fig. 5
Fig. 5
The brain structures impacted by chronic ocular hypertension (OHT) or POAG at the lateral geniculate and visual cortical levels are shown.
Fig. 6
Fig. 6
The deleterious effects glaucomatous optic neuropathy (GON) on retinal and brain structures and their dysfunctions resulting in various disabilities are depicted.

Similar articles

Cited by

References

    1. Abu-Amero K.K., Morales J., Bosley T.M. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2006;47(6):2533–2541. - PubMed
    1. Abu-Hassan D.W., Li X., Ryan E.I., Acott T.S., Kelley M.J. Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma. Stem Cell. 2015;33:751–761. - PMC - PubMed
    1. Addis V.M., Miller-Ellis E. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. Clin. Ophthalmol. 2018;12:2649–2657. - PMC - PubMed
    1. Adornetto A., Russo R., Parisi V. Neuroinflammation as a target for glaucoma therapy. Neural Regen. Res. 2019;14:391–394. - PMC - PubMed
    1. Adornetto A., Parisi V., Morrone L.A., et al. The role of autophagy in glaucomatous optic neuropathy. Front. Cell Dev. Biol. 2020;8:121. - PMC - PubMed

Further reading

    1. Abu-Hassan D.W., Acott T.S., Kelley M.J. The trabecular meshwork: a basic review of form and function. J. Ocul. Biol. 2014;2(1):9. - PMC - PubMed
    1. Acott T.S., Vranka J.A., Keller K.E., et al. Normal and glaucomatous outflow regulation. Prog. Retin. Eye Res. 2020;11 - PMC - PubMed
    1. Aihara M., Lu F., Kawata H., et al. Omidenepag Isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the Phase 3 AYAME Study. Am. J. Ophthalmol. 2020;220:53–63. - PubMed
    1. Aksar A.T., Yuksel N., Gok M., et al. Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis. Int. J. Ophthalmol. 2015;8(2):239–244. - PMC - PubMed
    1. Alvarado J., Murphy C., Polansky J., Juster R. Age-related changes in trabecular meshwork cellularity. Invest. Ophthalmol. Vis. Sci. 1981;21(5):714–727. - PubMed

LinkOut - more resources